• FDA deficiency and Additional Information (AI) response strategy

    An AI letter asks a specific scientific question, and how you answer it, not just what data you attach, determines whether the review closes. We help you respond to what's actually being asked, not what the letter seems to say on a first read.

  • Warning Letter response

    FDA evaluates Warning Letter responses on whether the root cause analysis is genuine and the CAPA is proportionate, not just whether a response was submitted. We help build both, and draft the response the way a reviewer needs to see it argued.

  • FDA Form 483 response

    Each 483 observation needs its own response addressing root cause and system-level correction, not just the specific instance cited. We work through the response observation by observation, with the 15-business-day clock in mind.

  • Recall strategy, classification planning, and FDA coordination

    Recall strategy decisions, and how you characterize the issue to FDA, shape how the agency classifies the recall and how much scrutiny follows. We help think through strategy and coordinate the FDA-facing process.

  • Field Safety Corrective Action (FSCA) planning and documentation

    FSCAs require coordinated planning across regulatory, quality, and often multiple markets simultaneously. We help structure the plan and the documentation FDA will expect to see.

  • Consent Decree advisory and Import Alert response strategy

    These represent the more severe end of FDA enforcement, and getting the response strategy right matters more, not less, at this stage. We advise on the regulatory and scientific dimensions of the response, working alongside legal counsel.

  • Lifecycle management

    Every device change is a fresh regulatory question, whether it needs a new submission, a supplement, or nothing at all. We help evaluate changes against current FDA guidance so lifecycle decisions stay defensible.